IV Insulin Protocols for Critically Ill Patients

When to Initiate IV Insulin

Start IV insulin therapy when blood glucose reaches ≥180 mg/dL (10 mmol/L) on two consecutive measurements in critically ill adults 1, 3
The same threshold of ≥180 mg/dL applies to critically ill children 4, 5
Before initiating insulin, evaluate and address reversible causes: dextrose-containing fluids, enteral/parenteral nutrition rates, and hyperglycemia-inducing medications (corticosteroids, vasopressors) 5
Continuous IV insulin infusion is strongly preferred over subcutaneous insulin in hemodynamically unstable patients, those with type 1 diabetes, and any critically ill patient with significant hyperglycemia 4, 6

Target blood glucose of 140-200 mg/dL (7.8-11.1 mmol/L) for all critically ill adults 2, 3
Avoid intensive glucose control targeting 80-139 mg/dL (4.4-7.7 mmol/L) as this significantly increases hypoglycemia risk without improving mortality or morbidity outcomes 2, 4
For critically ill children, the same conventional target of 140-200 mg/dL is recommended with a strong recommendation against intensive control 4, 5

Prepare insulin as a 1 unit/mL concentration in 0.9% sodium chloride using polyvinyl chloride infusion bags 7
Prime new IV tubing with a 20 mL waste volume before connecting to the patient to saturate binding sites in the tubing 7
Initial infusion rates typically start at 0.1 units/kg/hour for severe hyperglycemia, adjusted according to protocol 8

Monitor blood glucose every 30-60 minutes (≤1 hour intervals) during periods of glycemic instability until glucose stabilizes in target range 2, 4, 6
Once stable in target range, monitoring intervals can be extended but should remain frequent 4
Continuous or near-continuous glucose monitoring systems are preferred when available, though current evidence is insufficient to mandate their use over frequent point-of-care testing 7

Use a nurse-driven protocol with explicit computerized clinical decision support tools rather than paper-based protocols without decision support 2, 4, 5
Protocols with explicit decision support tools reduce hypoglycemia risk and improve time in target glucose range compared to protocols without such tools 2

Select protocols that demonstrate low hypoglycemia rates (<1% of measurements <70 mg/dL) in validation studies 1, 2
Treat any blood glucose <70 mg/dL immediately without delay 1, 5

Do not discontinue IV insulin until subcutaneous basal insulin has been administered and absorbed 6, 8
Calculate total daily subcutaneous insulin requirement as 80% of the total IV insulin used in the previous 24 hours 6
Give the first dose of basal insulin 1-2 hours before stopping the IV infusion to ensure adequate overlap 6, 8
Only transition when the patient is hemodynamically stable, off vasopressors, peripheral edema has resolved, and nutrition intake is predictable 7, 6

Check serum potassium every 4-6 hours initially as insulin therapy drives potassium intracellularly and can precipitate hypokalemia 8
Add potassium supplementation to IV fluids when serum potassium is in the low-normal range to prevent dangerous hypokalemia 8
If glucose remains >300 mg/dL (16.7 mmol/L) despite adequate insulin infusion, check for ketosis (urine ketones ≥2+ or serum ketones ≥1.5 mmol/L) 6, 8
Presence of ketosis with severe hyperglycemia indicates diabetic ketoacidosis requiring more aggressive insulin therapy (typically 0.1 units/kg/hour) 8

Never use sliding-scale insulin alone without basal insulin as this approach is ineffective and leads to poor glycemic control 6
Never abruptly stop IV insulin without overlapping subcutaneous basal insulin as this causes immediate loss of glucose control and rebound hyperglycemia 6, 8
Avoid targeting glucose <110 mg/dL as this increases hypoglycemia risk 2-fold without mortality benefit 2
Do not transition to subcutaneous insulin in patients with ongoing hemodynamic instability, hypothermia, significant peripheral edema, or frequent NPO status for procedures 7, 6
Avoid correcting glucose too rapidly (>50-75 mg/dL per hour) as this may cause neurological complications 8